Carlyle

Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (NASDAQ: CG) from Baxter International Inc. (NYSE: BAX). This marks a significant step in Vantive’s evolution as…